VeraMorph

VeraMorph is a private, preclinical biotech company leveraging a proprietary oral drug delivery platform to address the pervasive challenge of poor drug solubility, which affects ~90% of new small molecules and limits the efficacy of many approved drugs. The company employs a dual strategy: out-licensing its platform technology to pharmaceutical partners and building its own portfolio of clinically-differentiated oral drug products. Led by a seasoned team with deep expertise in formulation, manufacturing, and regulatory affairs, VeraMorph is supported by federal grants and external investment as it advances its technology and pipeline toward clinical translation.

Proprietary oral drug delivery platform (DPOD) designed to improve solubility and bioavailability of poorly soluble small molecule drugs.

VeraMorph competes in the crowded solubility enhancement market against established technologies like spray-dried dispersions, hot-melt extrusion, and lipid-based systems from both large CROs/CDMOs and specialized biotech firms. Differentiation will require demonstrating superior performance or broader applicability.